Quarterly report pursuant to Section 13 or 15(d)

Collaborative Arrangements - Global Development, Option and License Agreement, Strategic Collaboration Agreement, and Development Agreement (Details)

v3.20.2
Collaborative Arrangements - Global Development, Option and License Agreement, Strategic Collaboration Agreement, and Development Agreement (Details) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Oct. 31, 2017
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2019
Sep. 30, 2018
Dec. 31, 2017
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Contract with customer, liability   $ 4,056,000   $ 4,056,000   $ 2,044,000    
Revenue recognized   18,385,000 $ 21,906,000 48,023,000 $ 49,808,000      
Nestec Ltd. (Nestle Health Sciences) [Member]                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Revenue recognized   2,800,000 1,400,000 6,100,000 3,900,000      
Nestec Ltd. (Nestle Health Sciences) [Member] | Strategic Collaboration Agreement [Member]                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Contract with customer, liability             $ 600,000 $ 1,200,000
Nestec Ltd. (Nestle Health Sciences) [Member] | Global Development, Option and License Agreement [Member]                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Contract with customer, liability $ 14,000,000.0              
Revenue recognized   $ 0 $ 100,000 $ 0 $ 1,800,000      
Nestec Ltd. (Nestle Health Sciences) [Member] | Global Development, Option and License Agreement [Member] | Sales-Based Milestone [Member]                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Target sales for milestone 1,000,000,000.0              
Nestec Ltd. (Nestle Health Sciences) [Member] | Global Development, Option and License Agreement [Member] | Maximum [Member] | Research and Development Agreement [Member]                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Contingent receivable 85,000,000.0              
Nestec Ltd. (Nestle Health Sciences) [Member] | Global Development, Option and License Agreement [Member] | Maximum [Member] | Sales-Based Milestone [Member]                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Contingent receivable 250,000,000.0              
Nestec Ltd. (Nestle Health Sciences) [Member] | Global Development, Option and License Agreement [Member] | Milestone One [Member]                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Contract with customer, liability 4,000,000.0              
Nestec Ltd. (Nestle Health Sciences) [Member] | Global Development, Option and License Agreement [Member] | Milestone Two [Member]                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Contract with customer, liability $ 1,000,000.0              
Nestec Ltd. (Nestle Health Sciences) [Member] | CDX-6114 [Member]                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Cumulative catch-up adjustment to revenue, change in measure of progress           $ 3,000,000.0